Rahul Dutta1, Pariket M Dubal1, Peter F Svider2, James K Liu1,3,4, Soly Baredes1,4, Jean Anderson Eloy1,3,4,5. 1. Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A. 2. Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A. 3. Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A. 4. Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A. 5. Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: Sinonasal malignancies vary in behavior according to histology and anatomical location. Incidence, survival, and optimal treatment for these lesions are thus uncertain in various cases. Our objective was to utilize a national population-based registry to identify the most common sinonasal histopathologies by anatomical site, and subsequently analyze the data by incidence trends, survival rates, patient demographics, and treatment modalities. STUDY DESIGN: Retrospective analysis of the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry. METHODS: The SEER database was examined for patients diagnosed with sinonasal malignancies between 1973 and 2011. Data were stratified according to anatomical site, incidence, survival, histology, staging, and patient demographics. Therapy-based outcomes were analyzed for cases from 1983 to 2011. RESULTS: A total of 13,295 patients were identified, with an incidence of 0.83 per 100,000 people. Males comprised 58.6% of cases. Whites represented 81.5% of cases, while blacks comprised 8.7%. Squamous cell carcinoma was the most common histology (41.9%) across all sites of the sinonasal tract. The most common anatomical site of malignancy was the nasal cavity (45.7%), and least common was the frontal sinus (1.2%). For single sites, 5-year disease-specific survival (DSS) was highest for nasal cavity tumors (67.1%) and lowest for overlapping sinus malignancies (37.6%). The overall 5-year DSS for all sinonasal malignancies was 53.7%. CONCLUSION: Sinonasal malignancies are rare entities with poor overall prognosis. By anatomical site, prognosis is best for nasal cavity cancers and worst for overlapping lesions. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: Sinonasal malignancies vary in behavior according to histology and anatomical location. Incidence, survival, and optimal treatment for these lesions are thus uncertain in various cases. Our objective was to utilize a national population-based registry to identify the most common sinonasal histopathologies by anatomical site, and subsequently analyze the data by incidence trends, survival rates, patient demographics, and treatment modalities. STUDY DESIGN: Retrospective analysis of the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry. METHODS: The SEER database was examined for patients diagnosed with sinonasal malignancies between 1973 and 2011. Data were stratified according to anatomical site, incidence, survival, histology, staging, and patient demographics. Therapy-based outcomes were analyzed for cases from 1983 to 2011. RESULTS: A total of 13,295 patients were identified, with an incidence of 0.83 per 100,000 people. Males comprised 58.6% of cases. Whites represented 81.5% of cases, while blacks comprised 8.7%. Squamous cell carcinoma was the most common histology (41.9%) across all sites of the sinonasal tract. The most common anatomical site of malignancy was the nasal cavity (45.7%), and least common was the frontal sinus (1.2%). For single sites, 5-year disease-specific survival (DSS) was highest for nasal cavity tumors (67.1%) and lowest for overlapping sinus malignancies (37.6%). The overall 5-year DSS for all sinonasal malignancies was 53.7%. CONCLUSION:Sinonasal malignancies are rare entities with poor overall prognosis. By anatomical site, prognosis is best for nasal cavity cancers and worst for overlapping lesions. LEVEL OF EVIDENCE: 4.
Authors: Elizabeth D Stephenson; Saangyoung Eric Lee; Katherine Adams; Douglas R Farquhar; Zainab Farzal; Charles S Ebert; Matthew Ewend; Deanna Sasaki-Adams; Brian D Thorp; Adam M Zanation Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-10-01 Impact factor: 6.223
Authors: Nicholas R Lenze; Carolyn Quinsey; Deanna Sasaki-Adams; Matthew G Ewend; Brian D Thorp; Charles S Ebert; Adam M Zanation Journal: J Neurol Surg B Skull Base Date: 2021-05-29
Authors: Jennifer R Cracchiolo; Krupa Patel; Jocelyn C Migliacci; Luc T Morris; Ian Ganly; Benjamin R Roman; Sean M McBride; Viviane S Tabar; Marc A Cohen Journal: J Surg Oncol Date: 2017-11-28 Impact factor: 3.454